lindas have a posse
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
I believe we will have MHRA approval this year. If management thought it would be next year then they wouldn't be sending their millions of shares to GRATs which cost many tens of thousands to setup in attorney and accountant fees. In my personal opinion that makes a whole lot of sense to do before a massive appreciation in share value. It's ideal to do it when the share price remains low.
Remember that GRATs are specifically designed to transfer the appreciation from the assets in the GRAT during the term. For that reason, it is best to fund GRATs with assets that are expected to experience significant growth during the GRAT term, either through market movements for publicly traded assets or through a liquidity event for privately held investments.
Northwest Biotherapeutics in my opinion are very close to approval. We need to stay focused and not get distracted.
ASCO matters far more than a YouTube event.
It doesn't matter as they don't have Landmark Trial Results for rGBM and nGBM. We are much closer to market. Our technology happens to be superior though we will be able to buy up useful bolt on technologies, should that be desired, as we have the first mover advantage.
They don't have any matters before regulators. We have one drug in our pipeline which a vocal minority have been trying to stop.
There's simply no benefit in the medium to long term which would result from participating in this forum. Any short term pop in the stock would likely lead to a retrace given we are spoofed, naked shorted, and wash traded daily.
It's better that management act from a position of strength which will manifest in my personal opinion when we achieve UK approval.
Thank you it seems like world-class management cannot be stopped.
If Marnix Bosch appeared at the White House how many erroneous lawsuits and complaints would be filed arguing that Northwest Biotherapeutics are advertising an unapproved drug?
This tactic was already attempted to block UK approval.
I don't think management think this White House forum really matters since we already have these stakeholders behind DCVax:
FDA
MHRA
JAMA
Hundreds of top oncologists
Countless patient advocacy groups
Ultimately what's important? Approval not some roundtable on YouTube.
We are the only game in town for rGBM and nGBM.
Period!
Their pipeline has nothing even close to BLA or NDA.
https://www.chimerix.com/our-pipeline/
I don't care about other companies as they don't have our platform technology or Landmark Trial Data.
Ultimately a livestream forum would be nice for us though no doubt some would accuse us of advertising for an unapproved drug with matters before regulators.
Our world-class management remain in a quiet period rightly so given our paradigm-changing results.
Linda Liau could still show up or UCLA could get a mention as well as the generic name murcidencel. The firm wouldn't announce this with any significant lead time as doing so in the past only gave criminal manipulators the ability to stymie our efforts. For example Ashkan was prevented from presenting at ASCO due to that reason.
My mother nearly died from breast cancer. As somebody who knows about trials I will say that the Landmark Results will be approved in all jurisdictions.
If he didn't recommend Optune with DCVax then he would lose his funding from Notacure. The only way they don't go bankrupt would be riding on the DCVax coattails in a combination trial. Though will that work when the Brain Microwave literally burns the skin on your head?
Nothing was distorted.
Wait for the retrace
Let me axe you a question:
Do DCVax kill the tumor?
Wash trading is illegal.
50K shares on the ask.
Mouse trials isn't the same as Landmark Trial Data published in JAMA.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://pubmed.ncbi.nlm.nih.gov/37129737/
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
100 per share, son
Management are focused on estate planning it seems as well as obviously DCVax approval. The implications of the OTCQB filings are omnipresent to the rational observer.
Thank you Legend431 for your insight into NWBO.
https://voca.ro/1c7IXaVSsWhO
How many shares did Fife get in the last few loans he provided to NWBO? The answer? Zero.
I think you have a future working for Falun Gong but that's about the extent of your career.
You're welcome sir.
Dave Innes told me tonight via email that these changes are for estate planning purposes.
It's obvious we have a big event coming very soon in my personal opinion.
Management wouldn't be looking for tax shelters now if they thought the price would go further down or if we are a year away from a big material event.
Credit to George Bailey who actually read the document I posted.
GRATs are indeed exempt from SEC form 4 until the trust changes beneficiaries to anyone besides the grantor who created the trust.
Even if a trust is irrevocable, a transfer by a settlor-insider to a trust of which he’s the sole current beneficiary and investment trustee isn’t reportable by the insider. As a reminder, Rule 16a-8(c) ignores a remainder beneficiary’s interest in the trust for the purpose of determining the beneficial ownership of a trust holding such securities. In that connection, the SEC determined in Peter J. Kight that an insider may create a grantor retained annuity trust (GRAT) with securities without reporting the initial transfer and annuity payments between him and the GRAT pursuant to Rule 16a-13, so long as the settlor is both a trustee and the sole current beneficiary. Specifically, at least three types of transfers will occur during the term of the GRAT: (1) the initial transfer by the insider to the trustee of the GRAT; (2) annuity payments from the trustee to the grantor-insider pursuant to the GRAT’s terms; and (3) if the GRAT is successful, a final transfer of the remaining assets of the GRAT from for deferred reporting on a Form 5. If a principal stockholder-insider transfers securities by gift to a member of his immediate family sharing his household or to a trust for the benefit of such family member, the insider would typically continue to count such gifted securities for purposes of determining his 10 percent principal stockholder status. Further, if an insider (by principal stockholder status or otherwise) is serving as a trustee of such trust, Section 16 will deem him to own a pecuniary interest in such securities, although his interest therein would change from direct to indirect. In addition, Section 16 exempts transfers at death by will or by intestacy under Rule 16b-5.
Transfers to a trust must be listed on SEC Form 4. We haven't seen those filings yet.
https://www.skadden.com/-/media/files/publications/2017/03/securitieslawconsiderationsfortrustsandestatesadvi.pdf
https://www.investopedia.com/terms/f/form4.asp
Focusing on the ratio of GA vs RD expenses really makes little sense as none of us know what specific items are contained within each category. If you find these suspect then the appropriate action would be for you to sell shares. This would be very helpful to those who are buying. Thank you.
For the last quarter in fact General and Administrative costs are equal to Research and Development costs. Both were 6.8M for the quarter ending March 31st 2023. General and Administrative costs likely encompass efforts to get DCVax approved.
The loans which we took out over the past few years did not involve dilution. I don't expect the firm will rely upon dilution to fund their expenses. Yet the constant refrain from "concerned longs" always involves dilution. If the firm wanted to keep issuing more shares then their latest shelf offering would have been much larger.
We haven't seen any dilution in the past few years. I don't care if we are borrowing at high interest rates. We are an OTC biotech stock while rates have never been higher. That's a cost of doing business. If we need to borrow more I don't think that will be a problem given our Landmark Trial Results. We are easily a $100 stock on global approval for newly-diagnosed and recurrent GBM. That's a cure for cancer which many will pay huge multiples for given our potential for all solid tumors.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://pubmed.ncbi.nlm.nih.gov/37129737/
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
Transferring shares to their heirs now means management expect an explosive increase in value. I converted my traditional IRA to Roth last year for the same reason.
NWBO will be at $25 by end of the year. MHRA approval by Q4 2023 in my personal opinion.
Linda Powers owns more shares than anyone on this board so she obviously cares about the common share price as do other members of management and the board.
If you hate this management team so much then perhaps you should sell as it makes little sense to spend so much time posting about a company which are ran by those you do not trust. I would encourage you to choose that outcome as I am sure you would be happy owning something less stressful like QQQ.
Most financial advisors will keep their clients away from biotechnology as a sector especially now that we are in a bear market. I didn't invest in Northwest Biotherapeutics with the hope that pensioners would pile into this stock. I am looking at whether management can address global GBM demand. The investors will then follow.
We all know about the cash burn rate. This has been a challenge which management have dealt with for years. As a result of their investment in R&D we have a vaccine which could treat all solid tumors as well as multiple manufacturing processes to meet global demand for the GBM indication. That's $100 billion market cap for newly diagnosed and recurrent patients.
I really think your arguments are elementary distractions as we are already aware of this "risk" you cite which really happens to be a standard business practice in the biotechnology sector.
Those who didn't know about this fact, our R&D expenses, haven't done their due diligence.
They probably shouldn't own this stock.
The reasons I do are below.
https://jamanetwork.com/journals/jamaoncology/fullarticle/2798847
https://pubmed.ncbi.nlm.nih.gov/37129737/
http://nwbio.com/wp-content/uploads/NWBT-GBM-Summit-slides-3-15-23.pdf
https://investorshub.advfn.com/boards/read_msg.aspx?message_id=169815671
Northwest Biotherapeutics did not fund research of the trial investigators like Novocure does as their business strategy.
Since 2020 Northwest Biotherapeutics has had MHRA endorsement of their trial design via PIP and manufacturing process through MIA. MHRA have also allowed the export of DCVax to patients in other countries. Anyone who questions approval isn't a credible observer of the facts.
We also had Landmark Trial Results published in JAMA while researchers have also solved pseudoprogression using a new MRI technique. Flaskworks continues to progress while it seems like we will soon have manufacturing ramp up in Memphis with Charles River Labs. Northwest Biotherapeutics are far more derisked today than in 2020 which was when I became a shareholder. I am continuing to buy NWBO stock.
In my personal opinion longs should be doing that as much as possible. When it rains gold bring a bucket not a thimble! Those who remain excited are that way because they know the outcome given logical reasoning and rigorous due diligence.
Northwest Biotherapeutics has a plethora of angel investors who will back the firm come hell or high water.
None of the loans over the past few years involved shares as collateral. These unsecured loans showcase the confidence many have in the trial, management, and the market potential for DCVax.
That's exactly what happened with the SAP amendment.
Landmark Trial Data gets approved. Thanks again for the insight, Notacure!
Landmark Trial Results!
Landmark Trial Results!
MHRA Trial Endorsement (PIP)!
Innovative MHRA-endorsed Manufacturing!
Global Patent Protection!
My 500K shares should be worth $40M or more once Northwest Biotherapeutics obtains global approval on nGBM and rGBM indications.
I see no reason to sell my shares since I can borrow against them once NWBO are off OTC.
In my personal opinion as a retail investor representing myself alone, and not providing investment advice, longs must focus upon the deep value present in Northwest Biotherapeutics stock!
Billionaire Robert Hefner agrees:
Our Northwest Biotherapeutics (NWBO) investee “partner” likely has just made one of the biggest breakthroughs in the history of cancer. We know that is a really big statement so why do we at GHK believe that is possible? Because we believe the doors through which major cancer breakthroughs must pass are the human immune system, immunotherapies and personalized vaccines and NWBO has just leaped through those doors with its personalized DCVax vaccine made from your own cells.
You can argue about trial statistics until the cows come home but the bottom line is 1) people living longer 2) quality of life during treatments and 3) the cost of treatments.
During NWBO’s 16-year Phase III trial to treat glioblastoma (GBM), one of the most difficult and lethal of all solid tumor cancers 1) more people lived longer, 2) it is safe with virtually no side effects occurring and 3) NWBO estimates treatments will cost about half as much as Standard of Care chemotherapy and radiation treatments. So for the first time ever, GBM patients can have hope! And can hope like prayer increase the effectiveness and energy of the immune system? We think so.
We are aware we stuck our necks out when we said “possibly one of the biggest breakthroughs in the history of cancer”. So we have listed below our three principle reasons so you can decide for yourself:
After 417 failed GBM trials treating 31,952 patents over decades, DCVax-L is first treatment that gives GBM patients a meaningful chance to live longer, some now living 9 to as many as 19 years and counting.
DCVax was conceived and created not for glioblastoma alone but as a personalized tool of your own immune system to defeat all solid tumor cancers and that’s 90% of all cancers.
Since DCVax’s creation NWBO has amassed an enormous rich databank containing masses of information on patients, treatments, and DCVax’s use against 15 different solid tumor cancers that has not yet been analyzed by artificial intelligence (AI). We believe that in the near future when these vast amounts of data and information are teamed with AI and some of the world’s leading scientists and doctors that future generations of DCVax vaccines and protocols will experience great leaps forward in effectiveness at lower and lower costs for 90% of all cancers.
So to sum up, we believe NWBO with its DCVax immunotherapy personalized vaccines has leaped through the doors and will play a vital role in humanities great drive to defeat cancer once and for all.
Dr. Ashkan is the genius behind this viral vid of him performing brain surgery while his patient was awakened to play the violin…mid-surgery. He told me he champions DCVax-L bc of trial data along with what he’s seen first-hand from his patients. $NWBOhttps://t.co/XFTeSPFtH5
— Wade Kovash (@wkovash) June 6, 2022
Watch one of the world’s preeminent neurosurgeons explain the significance of $NWBO ‘s Phase III trial of DCVax-L. The results are groundbreaking and represent an enormous advancement in one of the most tragic cancers. https://t.co/eQw5tAsivK
— Wade Kovash (@wkovash) June 6, 2022